



LabCorp is Scheduled to Present at the Thomas Weisel Partners Healthcare Conference

September 6, 2006

BURLINGTON, N.C., Sept. 6 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that David P. King, Executive Vice President and Chief Operating Officer, Bradford T. Smith, Executive Vice President, Corporate Affairs, and William (Brad) Hayes, Executive Vice President and Chief Financial Officer, are scheduled to speak at the Thomas Weisel Partners Healthcare Conference in Boston, MA. LabCorp's presentation is planned for Thursday, September 7, 2006 at 3:15 p.m. (Eastern Time).

A live audio webcast of the presentation will be available via the Company Web site at www.labcorp.com and archived for replay.

About LabCorp

Laboratory Corporation of America(R) Holdings, a S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of \$3.3 billion in 2005, approximately 24,000 employees nationwide, and more than 220,000 clients, LabCorp offers clinical assays ranging from routine blood analyses to HIV and genomic testing. LabCorp combines its expertise in innovative clinical testing technology with its Centers of Excellence: The Center for Molecular Biology and Pathology, in Research Triangle Park, NC; National Genetics Institute, Inc. in Los Angeles, CA; ViroMed Laboratories, Inc. based in Minneapolis, MN; The Center for Esoteric Testing in Burlington, NC; DIANON Systems, Inc. based in Stratford, CT; US LABS based in Irvine, CA; and Esoterix and its Colorado Coagulation, Endocrine Sciences, and Cytometry Associates laboratories. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs, and pharmaceutical companies. To learn more about our growing organization, visit our Web site at: www.LabCorp.com.

Each of the above forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect LabCorp's financial results is included in the Company's Form 10-K for the year ended December 31, 2005, and subsequent SEC filings.

SOURCE Laboratory Corporation of America Holdings

-0-

09/06/2006

/CONTACT: Investor, Scott Fleming, +1-336-436-4879, or Media, Pam Sherry,
+1-336-436-4855, both of LabCorp; or Shareholder Direct, +1-800-LAB-0401/
/Web site: <http://www.labcorp.com/>
(LH)

CO: Laboratory Corporation of America Holdings; LabCorp; Thomas Weisel
Partners Healthcare Conference
ST: North Carolina, Massachusetts
IN: HEA MTC BIO
SU: CCA MAV

KM-WB

-- CLW009 --

0774 09/06/2006 13:09 EDT <http://www.prnewswire.com>